One-Shot hope: drug may shield fertility in women facing stem cell transplant

NCT ID NCT07552480

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a single injection of goserelin, given just before a stem cell transplant, can help preserve ovarian function in women with blood cancers. The trial will enroll 64 women aged 14-50 and measure menstrual recovery six months after transplant. If successful, it could reduce the risk of early menopause and infertility caused by the transplant conditioning regimen.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
goserelin
What this could lead to
If it works, this could offer a way to protect fertility and ovarian function in women who need a stem cell transplant for blood cancer.
What could go wrong
This is a small, early-stage trial with only 64 participants. It may not show a clear benefit, and goserelin could cause side effects like hot flashes or mood changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, 450000, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310000, China

  • The First People's Hospital of Yunnan Province

    Kunming, Yunnan, 650000, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430000, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.